louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02031757: Effectiveness of Controlled-perturbation Gait Training on Gait Rehabilitation and Fear of Falling in Individuals With Gait Impairments
Official title: The Effectiveness of Controlled-perturbation Gait Training on Gait Rehabilitation and Fear of Falling in Individuals With Gait Impairments.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cerebrovascular Disorders
Peripheral Nervous System Diseases
Musculoskeletal Diseases
Joint Diseases
Keywords: Balance control
Aging
Balance reactions
Perturbation
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2014-01-09
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Gait dysfunction often occurs following stroke, neurological or musculoskeletal disease, injury and surgery. One of the consequences of such deficit is an increased risk of fall and injury. A gait training regime that incorporates controlled perturbation has been found to reduce falls in elderly population but the effectiveness of such training has yet to be studied.

The aim of this study is to evaluate the effectiveness of specific controlled dynamic perturbation training, during gait, on gait rehabilitation, fear of falling and falling with gait impaired individuals. Perturbation will be performed using a specifically designed system that provides small, controlled and unpredictable perturbations during treadmill walking.

Detailed description: A total of 100 adults with gait dysfunction will be enrolled, evaluated and trained. They will be randomly assigned to two groups: perturbation training group and balance exercises group. Both groups will receive standard physiotherapy treatments. No gender based differences are expected so we will be able to pool male and female individuals for this analysis. Each subject of the experimental and of the control groups will be trained on 12 occasions over a period of 10-12 weeks (15 minutes, 2-3 times/week) in addition to standard care physiotherapy. Gait, balance function and fear of falling will be tested in both groups before, immediately after, 3 and 6 months after completion of the training period to explore the benefit of training.

Eligibility criteria: Inclusion Criteria:

* Ambulatory capability of over 2 in Functional Ambulation Classification .
* No less then 4 weeks following surgery.
* preserved mental capacity.

Exclusion Criteria:

* less then 4 weeks following surgery or injury.
* Symptomatic orthostatic hypotension, respiratory or cardiovascular, disorders that may interfere with participation in the perturbation program.

Primary outcomes:
measure: short Falls Efficacy Scale International (FES-I)
timeFrame: up to 6 months
Secondary outcomes:
measure: Berg Balance Scale
timeFrame: UP TO 6 MONTHS
measure: BalanceMaster LIMITS OF STABILITY (LOS) test
timeFrame: up to 6 months
Other outcomes:
Locations:
city: Jerusalem,
country: Israel
facility: Hadassah Medical Organization,
Study officials:
References:
Clinical trial NCT06918457: A Clinical Trial With a Self-controlled, Multicenter, Pediatric EEG Intelligent Analysis System to Assist in Diagnosis
Official title: A Clinical Trial With a Self-controlled, Multicenter, Pediatric EEG Intelligent Analysis System to Assist in Diagnosis
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Pediatric Epilepsy
Lead sponsor: Kunming Children's Hospital
Sponsor class: OTHER
First posted: 2025-04-09
Enrollment: 1000
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: children aged \< 18 years old with suspected epilepsy who need EEG examination

Brief summary: A diagnostic accuracy study on Artificial intelligence EEG analysis system assisted doctors to diagnose pediatric epilepsy.


Eligibility criteria: Inclusion Criteria:

* Age \< 18 years old
* Children with suspected epilepsy

Exclusion Criteria:

* During EEG monitoring, the patients had other serious neurological diseases and mental diseases concurrently
* Used medication that affect EEG data within 3 weeks, such as sedatives and anti-epileptic medications
* Substandard data quality, such as data lack of key records, electrode connection discontinuity, insufficient recording time, or the presence of serious artifacts
* Incomplete or missing data
* Equipment or operational abnormalities, data for which EEG monitoring has not been performed continuously

Primary outcomes:
measure: To evaluate the coincidence rate between doctors' independent diagnosis and the diagnosis recommended by the AI system.
timeFrame: Within 48 hours after the completion of EEG monitoring
Secondary outcomes:
measure: To evaluate the diagnostic efficiency of clinicians at two-stage
timeFrame: Immediately after the end of EEG interpretation
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05072457: Benefit of Assistive Listening Device for Lateralization
Official title: Benefit of Assistive Listening Device for Lateralization and Spatial Hearing
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hearing Loss, Sensorineural
Lead sponsor: Sonova AG
Sponsor class: INDUSTRY
Collaborators: name: Hearts for Hearing
First posted: 2021-10-11
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: Speech intelligibility in noise will be evaluated in adults with moderate to moderate-severe sensorineural hearing loss using a Phonak Roger microphone and hearing aid with compatible Phonak Roger receiver. Target speech will be presented from multiple directions while competing diffuse background noise is presented simultaneously. Participants will repeat back words and percent correct is calculated.


Eligibility criteria: Inclusion Criteria:

* Experienced hearing aid users, age 18 or older
* Bilateral, symmetric moderate to moderate-severe sensorineural hearing loss
* Good understanding of the English language
* Health outer ear as confirmed by otoscopy
* Informed consent as documented by signature

Exclusion Criteria:

* Contraindications to the medical device noted upon otoscopy
* Known hypersensitivity or allergies to materials of the investigations device or comparator
* Inability to produce reliable test results
* Known psychological problems
* Self reported symptoms of vertigo or dizziness

Primary outcomes:
measure: Lateralization Hearing Ability
timeFrame: Day 1 of 1 day study
measure: Spatial Hearing Ability
timeFrame: Day 1 of 1 day study
Secondary outcomes:
Other outcomes:
Locations:
city: Oklahoma City
country: United States
facility: Hearts for Hearing
state: Oklahoma
Study officials:
References:
Clinical trial NCT03468257: Testing a Novel Stress-induced Eating Intervention for Cancer Prevention
Official title: Testing a Novel Stress-induced Eating Intervention for Cancer Prevention
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: 7-dose Control - Progressive Muscle Relaxation Only
5-dose - Pairs Progressive Muscle Relaxation With Fruit 5 Consecutive Days
7-dose - Pairs Progressive Muscle Relaxation With Fruit 7 Consecutive Days
9-dose - Pairs Progressive Muscle Relaxation With Fruit 9 Consecutive Days
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
First posted: 2018-03-16
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Subjects will be enrolled in a stress-induced eating intervention with 5, 7, or 9 treatments or control. Treatment will comprise imagining a stressful event, engaging in a stress relief activity (Progressive Muscle Relaxation), and consuming a fruit once per day. There will be one lab visit at baseline in which participants undergo an acute laboratory stressor (i.e., speech and math tasks) and consume food from a buffet. There will be another lab visit at two weeks post-intervention. In the second (and final) lab visit, participants will repeat the acute laboratory stressor (i.e., speech and math tasks) and buffet, and additionally complete questionnaires about their experience in the study.


Eligibility criteria: Inclusion Criteria:

* age 18 or older
* fluent in English
* access to an internet-connected device
* reporting a neutral taste and moderate novelty for at least one fruit
* reporting household size-adjusted income less than or equal to 200% of the federal poverty threshold
* perceived stress scale score of 21.82 (1 SD above the national mean)
* BMI 25
* scoring 3.23 on the Dutch Eating Behavior-Emotional Eating Questionnaire

Exclusion Criteria:

* on a diet that would compel them to refrain from eating food in the laboratory buffet
* allergy to any foods presented in the buffet
* selecting a fruit as one or more of top three choices of foods that would make them feel better if stressed

Primary outcomes:
measure: Healthy Eating Index
timeFrame: 14 days after last dose
Secondary outcomes:
measure: Calorie intake
timeFrame: 14 days after last dose
measure: Acceptability/Credibility
timeFrame: 14 days after last dose
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02226757: Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients
Official title: Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients After Progression on TKI-treatment; a Pilot-study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: NSCLC
HER2-expression
EGFR-mutation
Keywords: NSCLC
HER2-expression
EGFR-mutation
Trastuzumab
Paclitaxel
Lead sponsor: Amsterdam UMC, location VUmc
Sponsor class: OTHER
First posted: 2014-08-27
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is a pilot study in EGFR-mutated NSCLC patients who have progressed on standard-dose TKIs. Tumor biopsies will be evaluated for HER2-expression. In case of HER2 expression, patients can participate in the trial after obtaining informed consent.

Patients will be treated with weekly paclitaxel-trastuzumab.


Eligibility criteria: Inclusion Criteria:

* Histologically confirmed stage IV non-squamous NSCLC patients.
* Patients must have been detected with an activating EGFR mutation at baseline and must have yet progressed on erlotinib, gefitinib or afatinib monotherapy in daily dose of 150 mg, 250 mg or 40 mg respectively. (Patients with unknown mutation status that have exhibited a response to these agents or stable disease for at least 6 months while on treatment with gefitinib or erlotinib are also eligible).
* Rebiopsy after having acquired resistance to TKI-treatment must have been performed and HER2-overexpression (positive immunohistochemistry staining) must have been detected.
* There must be at least one measurable disease site, according to RECIST 1.1 criteria.
* WHO performance status 0-2.
* Willing and able to comply with the study prescriptions.
* 18 years or older.
* Not pregnant or breast feeding and willing to take adequate contraceptive measures during the study.
* Ability to give written informed consent before patient registration.

Exclusion Criteria:

* No uncontrolled infectious disease.
* No other active malignancy.
* No major surgery (excluding diagnostic procedures like e.g. mediastinoscopy or VATS biopsy) in the previous 4 weeks.
* No treatment with investigational drugs.
* No known hypersensitivity to trastuzumab-paclitaxel
* No symptomatic brain metastases.
* History of coronary artery disease, NYHA class III or IV and Left Ventricular Ejection Fraction (LVEF) of \<45%.

Primary outcomes:
measure: Objective response rate
timeFrame: 6 weeks
Secondary outcomes:
measure: Disease control rate
timeFrame: 6 weeks
measure: progression-free survival
timeFrame: 2 years
measure: Toxicity
timeFrame: 2 years
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: VU University medical Center
Study officials:
References:
Clinical trial NCT06611657: Antirotinib Hydrochloride Plus Whole Brain Radiotherapy for Small Cell Lung Cancer With Brain Metastases
Official title: Anlotinib Hydrochloride Combined With Whole Brain Radiotherapy for the Treatment of Brain Metastases in Small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Whole Brain Radiotherapy
Lead sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sponsor class: OTHER
First posted: 2024-09-25
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The objective of this study was to evaluate the efficacy and safety of whole brain radiotherapy combined with antirotinib hydrochloride in the treatment of brain metastases in small cell lung cancer

Detailed description: This was a single-center, single-arm trail. Enrolled patients were pathologically diagnosed with small cell lung cancer and had completed at least 4 cycles of first-line chemotherapy. Patients with brain metastases at first visit or during treatment were treated with whole brain radiotherapy combined with anlotinib hydrochloride. Oral antirotinib was started 2 weeks before radiotherapy for brain metastases and stopped for 1 week after 2 weeks. After radiotherapy, antirotinib was continued until tumor progression. Efficacy and toxicity data were collected for evaluation and analysis.

Eligibility criteria: Inclusion Criteria:

1. Small cell lung cancer confirmed by pathology, completion of at least 4 cycles of first-line chemotherapy, and measurable disease according to RECIST criteria.
2. The expected survival time is more than 3 months.
3. Intracranial metastases ≤10.
4. Adequate organ and bone marrow function.

Exclusion Criteria:

1. Patients who have used antiangiogenic drugs within the previous 1 month.
2. Non-small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer).
3. Small cell lung cancer with hilar invasion or hemoptysis.
4. Patients with intracranial acute, subacute cerebral infarction, intracranial lesions acute, subacute hemorrhage.
5. An unresolved acute toxic reaction period higher than grade 2 of CTC-AE(4.0) due to any prior treatment.
6. Advanced patients with severe symptoms, tumors that have spread to the internal organs, and a short-term risk of life-threatening complications.
7. Patients with life-threatening conditions of other severe and/or uncontrolled diseases.

Primary outcomes:
measure: Intracranial progression-free survival
timeFrame: 6 months
Secondary outcomes:
measure: Overall Survival
timeFrame: 1 year
measure: progression-free survival
timeFrame: 6 months
Other outcomes:
Locations:
city: Beijing
country: China
facility: Cancer Hospital Chinese Academy of Medical Sciences
state: Beijing
Study officials:
affiliation: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
name: Lei Deng, MD
role: STUDY_CHAIR
References:
Clinical trial NCT06334757: Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
Official title: A Multi-center, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Serplulimab Plus Bevacizumab and Chemotherapy for EGFRm+ Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Lead sponsor: Henan Cancer Hospital
Sponsor class: OTHER_GOV
First posted: 2024-03-28
Enrollment: 46
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy and safety of Serplulimab Plus Bevacizumab and chemotherapy in TKI-resistant EGFR-mutated non-squamous NSCLC Chinese patients.


Eligibility criteria: Inclusion Criteria:

1. Signed written informed consent before any trial-related processes;
2. Age ≥ 18 years and ≤70 years male or females;
3. Has a histologically or cytologically confirmed stage IIIB/IIIC (American Joint Committee on Cancer \[AJCC\] 8th edition) NSCLC that is unresectable and not fit for radical concurrent chemoradiotherapy, or metastatic / recurrent non-squamous NSCLC;
4. Patients with EGFR mutation confirmed by tumor histology or cytology or hematology prior to EGFR-TKI treatment
5. EGFR-TKI resistance, confirmed by RECIST 1.1
6. The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1;

Exclusion Criteria:

1. History of severe allergies to any study drug
2. Has previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or any other stimulatory or inhibitory agents of T cell receptors
3. Previous exposure to VEGF inhibitor for anti-cancer treatment
4. Patients with untreated symptomatic brain metastases. Patients with treated brain metastases will be allowed if brain imaging obtained greater than 4 weeks from trial enrollment reveals stable disease.
5. Has received a live-virus vaccination within 28 days of planned treatment start
6. Interstitial lung disease or pneumonitis requiring oral or IV glucocorticoids Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study

Primary outcomes:
measure: ORR(Overall Response Rate)
timeFrame: From start of treatment to 12 months
Secondary outcomes:
measure: PFS(Progression Free Survival)
timeFrame: From start of treatment to 24 months
measure: OS(Overall Survival)
timeFrame: From start of treatment to 24 months
measure: AE(Adverse Event)
timeFrame: From start of treatment to 24 months
Other outcomes:
Locations:
city: Zhengzhou
country: China
facility: Henan Cancer Hospital
state: Henan
Study officials:
References:
Clinical trial NCT04921657: Genome-wide Analysis of Lipid-lowering Efficacy and Drug Level of Simvastatin and Rosuvastatin
Official title: Genome-wide Analysis of Lipid-lowering Efficacy and Drug Level of the Two Commonly Used Statins, Simvastatin and Rosuvastatin.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypercholesterolemia
Keywords: Statins
Pharmacogenomics
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2021-06-10
Enrollment: 362
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with hypercholesterolemia attending medical clinics in Hong Kong who were eligible for statin treatment according to local guidelines in Hong Kong and willing to give informed consent for DNA analysis.

Brief summary: This study will perform a genome-wide association study (GWAS) of the lipid responses to rosuvastatin and simvastatin and plasma concentrations of these two statins in a homogeneous group of Han Chinese patients.

Detailed description: A GWAS will be performed on about 360 Han Chinese patients with hypercholesterolaemia (which may be familial or non-familial) who have previously participated in a research project on the pharmacogenetics of statins and who have been treated with rosuvastatin and simvastatin to determine the genetic factors that may be related to the reduction in plasma low-density lipoprotein cholesterol (LDL-C) and plasma concentrations of these two statins. The lipid profiles were measured at baseline on no lipid-lowering treatment and after 4-6 week treatment of rosuvastatin 10 mg daily and after treatment with simvastatin 40 mg daily for at least 6 weeks with at least a 4-week washout period between the two treatments. Plasma concentrations of these two statins and their active metabolites about 12 hours after administration of statins have been measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Genotyping for the whole-genome scan will be carried out on the Illumina OminiExpress beadchip (Illumina, San Diego, CA). The samples will be processed using the Illumina iScan platform at the Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong (CUHK).

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of hypercholesterolemia (familial or non-familial)
* Eligible for statin treatment according to local guidelines in the Hong Kong Public Hospital system.

Exclusion Criteria:

* Taking other medication which may interact with the pharmacokinetics or lipid response to statins.
* Not willing to cooperate with study requirements.

Primary outcomes:
measure: Genome-wide analysis of DNA sample
timeFrame: DNA samples taken after 4 weeks on statin treatment.
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Brian Tomlinson
Study officials:
affiliation: Chinese University of Hong Kong
name: BRIAN TOMLINSON, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00902057: Desmopressin for Bleeding Related to Low Body Temperature
Official title: Effect of Desmopressin on Platelet Dysfunction Associated With Mild Hypothermia in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Hypothermia Induced Impairment of Primary Haemostasis
Lead sponsor: The University of Hong Kong
Sponsor class: OTHER
First posted: 2009-05-14
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To study, with a prospective randomised controlled design, whether the subcutaneous administration of the haemostatic drug desmopressin, may improve the impairment of primary haemostasis due to mildly decreased temperature.


Eligibility criteria: Inclusion Criteria:

1. Healthy volunteers

Exclusion Criteria:

1. Any known platelet or coagulation disorder.
2. Pregnant or lactating women.
3. Known chronic liver or renal disease.
4. Coronary artery, carotid artery or peripheral artery disease
5. Recent history of taking antiplatelet drugs, anticoagulants or herbal preparations.
6. Smoker or alcohol user
7. Mentally incapable of providing informed consent
8. Students or junior staff members who had direct working relationship with the PI

Primary outcomes:
measure: closure time on PFA-100
timeFrame: 3 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: The University of Hong Kong
state: Hong Kong
Study officials:
References: